Loading
A phase 3 trial of Nemtabrutinib, Fludarabine, Cyclophosphamide, Bendamustine and Rituximab in chronic lymphocytic leukaemia, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) is a phase 3 interventional study registered as NCT05624554 by Merck Sharp & Dohme LLC, with 300 participants enrolled, started 2023-03-16 and due to reach its primary completion in 2027-05-19. Interventions recorded: Nemtabrutinib, Fludarabine, Cyclophosphamide, Bendamustine, Rituximab and Truxima.
Shares Fludarabine, Chronic lymphocytic leukaemia, first treatment, Rituximab, Cyclophosphamide and the tag pipeline.
Shares Bendamustine, Chronic lymphocytic leukaemia, first treatment, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Nemtabrutinib, Rituximab, Chronic lymphocytic leukaemia, Merck & Co. (MSD) and the tag pipeline.
Shares Chronic lymphocytic leukaemia, first treatment, Rituximab, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Bendamustine, Rituximab, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Bendamustine, Rituximab, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.